Forbion
Leading European life sciences venture capital firm focused on therapeutics. One of the most active biotech investors in Europe with deep scientific expertise and strong track record of building successful companies.
Website
https://forbion.comLocation
Naarden, Netherlands
Founded
2006
AUM
€3B+
Investment Range
€5M - €50M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth
Investment Thesis
Forbion invests in innovative life sciences companies primarily in Europe and the US, focusing on therapeutics with differentiated approaches and strong clinical potential. They take an active role in company building, providing strategic guidance and leveraging their extensive network in the pharmaceutical industry.
Team
Partners / Managing Directors (Health & Bio Focus)
- Geert-Jan Mulder - Managing Partner
- Sander Slootweg - Managing Partner
- Martijn Kleijwegt - Managing Partner
- Roel Bulthuis - Managing Partner
Other Key Team Members
- Holger Reithinger, PhD - Partner
Focus Areas
- Therapeutics
- Oncology
- Rare Diseases
- Immunology
- Neuroscience
- Gene & Cell Therapy
- European Life Sciences
Notable Exits
- Kite Pharma - Acquired (2017, by Gilead for $11.9B)
- Merus - IPO (2016, NASDAQ: MRUS)
- ProQR Therapeutics - IPO (2014, NASDAQ: PRQR)
- argenx - IPO (2017, NASDAQ: ARGX)